April 1, 2023 – Augnition Labs announced today that the company will be one of the featured sponsors at the 2023 International Conference on Learning and Memory (LEARNMEM™2023), which will be held on April 26-30 against the scenic backdrop of…
August 23, 2022 – Augnition Labs announced today that the National Institute on Aging (NIA) part of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research grant to develop and scale its Augmem™ Platform.…
July 21, 2022 – Augnition Labs today announces the inclusion of their Cognitive Test Suite, Augmem™ as part of the University of Arizona Precision Aging Network’s Mindcrowd 2.0. Funded through a $60M five-year grant from the National Institutes of Health,…
Copyright © 2023 Augnition Labs, LLC.
Dr. Peters has over 20 years of experience in translational research, target discovery, and small molecule discovery for CNS indications. He built and managed small and large research teams, and his work has contributed to the discovery, progression, and clinical development of small molecule therapeutics for the treatment of multiple neurological indications including stroke, Alzheimer’s Disease, Parkinson’s disease, pain, and schizophrenia. He currently serves as vice president and head of translational science at Longboard Pharmaceuticals. Peters built the departments of Neurobiology and Behavioral Pharmacology, and managed target identification, in vivo pharmacology, and lead optimization at Dart Neuroscience. His work contributed to the advancement of multiple compounds into clinical development, and led to a broad intellectual property portfolio focused on enhancement of brain plasticity and cognitive function. Peters has a M.Sc. in Biochemistry from the Freie Universität Berlin, Germany and a PhD in Neuroscience from the University of London, UK. He conducted postdoctoral work on Alzheimer’s disease with Tetsuyuki Maruyama at Merck Sharp & Dohme (UK).
